Curebus (CEO Seong-jin Cho) , a company developing treatments for central nervous system (CNS) diseases, announced on the 7th that it was selected for the '2025 Global Cluster R&BD Project' hosted by the Ministry of Science and ICT's Research and Development Special Zone Promotion Foundation, along with the Korea Institute of Science and Technology (KIST) and Italian pharmaceutical company Angelini Pharma.
This government project supports domestic research institutes and companies in conducting joint research and development with leading overseas clusters. The goal is to strengthen innovation capabilities between the two countries and foster a sustainable global cooperative ecosystem through technology-based collaboration, with research funding of up to 3 billion won provided.
Through this project, CureVerse plans to form a Europe-based global cluster consortium with KIST and Angelini Pharma, and conduct joint research on the potential expansion of the indications for CV-01, a candidate for the treatment of central nervous system diseases. Furthermore, the company plans to explore the long-term establishment of a joint new drug development platform between Korea and the EU.
CV-01 is a small-molecule drug candidate targeting the Keap1/Nrf2 pathway, currently undergoing Phase 1 clinical trials at Seoul National University Hospital. For this project, KIST will conduct nonclinical efficacy evaluations based on animal models to expand indications, while Angelini Pharma will be responsible for developing clinical development and commercialization strategies in Europe. Cureverse will coordinate inter-cluster collaboration across the project and oversee the global commercialization strategy.
CEO Cho Seong-jin expressed his expectation that the selection of this project will further strengthen the foundation for joint research between Korea and Europe, and that he plans to expand the indications of CV-01 to include Lou Gehrig's disease and degenerative brain diseases, thereby increasing the possibility of entering the global market.
Meanwhile, Curebus, a research institute located in the Hongneung Special Zone in Seoul, has been building a foundation for technological advancement and commercialization through selection for regional specialization development projects (H-Trian and Bridge) in 2021 and 2022 and customized consulting from the Hongneung-Chuncheon Venture Support Platform (HC-VIP). In 2022, it won the grand prize at the GRaND-K Startup School, an audition-style startup support program.
- See more related articles
You must be logged in to post a comment.